基于多对比MRI的影像组学可精确鉴别胶质瘤亚型并预测肿瘤增殖行为
该回顾性研究纳入220例病理确诊的胶质瘤,基于解剖、弥散和灌注MRI共10种对比图提取431个影像组学特征,分析其与肿瘤分级及Ki-67标记指数的相关性,并构建多变量模型。多对比联合影像组学特征在鉴别胶质瘤亚型和预测增殖水平方面均获得最高AUC,分别达0.997(II级 vs IV级)和0.936。结论认为多对比影像组学可提供几何特征和分子生物学特征的互补信息,可能有助于术前个体化诊断。
要点
- 多对比MRI影像组学特征与胶质瘤分级及Ki-67标记指数显著相关。
- 多模态MRI在评估胶质瘤病理行为方面提供独立但互补的信息。
- 联合多对比MRI影像组学可较精确地预测胶质瘤亚型和增殖水平。
核心结论
- 多对比影像组学提供几何特征和分子生物学特征的互补信息,与肿瘤分级和增殖显著相关;联合所有对比图的影像组学模型可能较精确地预测胶质瘤生物学行为,可能有助于术前个体化诊断。
研究设计与样本
- 回顾性分析纳入220例病理确诊的胶质瘤和10种对比图;图像配准至T2FLAIR并各向同性重采样至1 mm³,在半自动定义的肿瘤体积内从每张对比图提取431个影像组学特征;采用偏相关分析揭示特征与病理生物标志物的相关性,并以调整的0.632+ bootstrap AUC构建多变量模型筛选最佳预测模型。
诊断标准与关键数值
- 单变量分析中,非小波和小波影像组学特征均与肿瘤分级及Ki-67标记指数显著相关;肿瘤分级在T1C的最大R为0.557(p=2.04E-14),Ki-67在ADC的最大R为0.395(p=2.33E-07);多变量分析中,联合所有对比图的影像组学特征在鉴别胶质瘤亚型和预测增殖方面AUC均最高,优于单对比图;低级别/高级别胶质瘤最佳AUC为0.911;鉴别胶质瘤亚型时,II-III级最佳AUC为0.896,II-IV级为0.997,III-IV级为0.881;预测增殖水平时,多对比特征AUC为0.936。
临床应用与阅片要点
- 作者认为联合所有对比图的影像组学模型可能较精确地预测胶质瘤生物学行为,可能有助于术前个体化诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To explore the feasibility and diagnostic performance of radiomics based on anatomical, diffusion and perfusion MRI in differentiating among glioma subtypes and predicting tumour proliferation.
METHODS: 220 pathology-confirmed gliomas and ten contrasts were included in the retrospective analysis. After being registered to T2FLAIR images and resampling to 1 mm3 isotropically, 431 radiomics features were extracted from each contrast map within a semi-automatic defined tumour volume. For single-contrast and the combination of all contrasts, correlations between the radiomics features and pathological biomarkers were revealed by partial correlation analysis, and multivariate models were built to identify the best predictive models with adjusted 0.632+ bootstrap AUC.
RESULTS: In univariate analysis, both non-wavelet and wavelet radiomics features were correlated significantly with tumour grade and the Ki-67 labelling index. The max R was 0.557 (p = 2.04E-14) in T1C for tumour grade and 0.395 (p = 2.33E-07) in ADC for Ki-67. In the multivariate analysis, the combination of all-contrast radiomics features had the highest AUCs in both differentiating among glioma subtypes and predicting proliferation compared with those in single-contrast images. For low-/high-grade gliomas, the best AUC was 0.911. In differentiating among glioma subtypes, the best AUC was 0.896 for grades II-III, 0.997 for grades II-IV, and 0.881 for grades III-IV. In predicting proliferation levels, multicontrast features led to an AUC of 0.936.
CONCLUSION: Multicontrast radiomics supplies complementary information on both geometric characters and molecular biological traits, which correlated significantly with tumour grade and proliferation. Combining all-contrast radiomics models might precisely predict glioma biological behaviour, which may be attributed to presurgical personal diagnosis.
KEY POINTS: • Multicontrast MRI radiomics features are significantly correlated with tumour grade and Ki-67 LI. • Multimodality MRI provides independent but supplemental information in assessing glioma pathological behaviour. • Combined multicontrast MRI radiomics can precisely predict glioma subtypes and proliferation levels.
引用
- Su C, Jiang J, Zhang S, et al. Radiomics based on multicontrast MRI can precisely differentiate among glioma subtypes and predict tumour-proliferative behaviour. Eur Radiol. 2018. PMID: 30315419. doi:10.1007/s00330-018-5704-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。